IL6 and COVID-19: However, according to numerous investigators, the inflammatory response observed in COVID-19 patients can be considered mild if compared to the one observed in typical ARDS and in cytokine-release syndrome [212,213,214,215]: indeed, in ARDS patients, levels of interleukin-1β and interleukin-6 have been shown to be 10 to 60 fold higher than in COVID-19 [216,217].